Consensus Travere Therapeutics, Inc.

Equities

TVTX

US89422G1076

Market Closed - Nasdaq Other stock markets 04:00:04 2024-04-23 pm EDT			5-day change	1st Jan Change
5.74 ^USD	-1.88%		-4.17%	-36.15%

Apr. 03	Travere Therapeutics to Present Abstracts on Filspari® in Iga Nephropathy At World Congress of Nephrology and the American Nephrology Nurses Association	CI
Mar. 28	North American Morning Briefing : Stocks Set for -2-	DJ

Evolution of the average Target Price on Travere Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

e93b6e5a1d2ab8ac66688.tNZSwkKMGYLRrBFnaiJCE26dgkI-m0rm_-6hNlSjhqQ.14Uls3TKa86J7yMNBxsscSes6zdk7yKtiKvYbjHw1PL94zD1BMV81abbQA~a741600d9d404e815615083c1e4e51ec

Analyst Recommendations on Travere Therapeutics, Inc.

Wedbush Lifts Travere Therapeutics' Price Target to $13 From $12, Keeps Outperform Rating	Jan. 29	MT
Stifel Adjusts Price Target on Travere Therapeutics to $10 From $8, Maintains Hold Rating	Dec. 18	MT
Citigroup Upgrades Travere Therapeutics to Buy From Neutral, Raises Price Target to $10 From $7	Dec. 05	MT
JPMorgan Adjusts Travere Therapeutics Price Target to $19 From $23, Maintains Overweight Rating	Nov. 24	MT
Citigroup Initiates Travere Therapeutics With Neutral Rating, $7 Price Target	Nov. 20	MT
Canaccord Genuity Cuts Travere Therapeutics Price Target to $15 From $35, Maintains Buy Rating	23-10-03	MT
Guggenheim Cuts Travere Therapeutics' Price Target to $18 From $25, Keeps Buy Rating	23-09-22	MT
Evercore ISI Adjusts Price Target on Travere Therapeutics to $14 From $30, Maintains Outperform Rating	23-09-22	MT
HC Wainwright Adjusts Travere Therapeutics' Price Target to $18 From $32, Keeps Buy Rating	23-09-22	MT
Wells Fargo Downgrades Travere Therapeutics to Equal Weight From Overweight, Adjusts Price Target to $8 From $24	23-09-22	MT
Wedbush Lowers Travere Therapeutics' PT to $12 From $23, Revises Estimates to Assume 'Worst-Case Scenario' With Filspari Remaining on US Market Through 2026; Keeps Outperform Rating	23-09-22	MT
William Blair Downgrades Travere Therapeutics to Market Perform From Outperform	23-09-21	MT
Evercore ISI Reinstates Travere Therapeutics at Outperform, $30 Price Target	23-09-06	MT
Piper Sandler Adjusts Travere Therapeutics' Price Target to $19 From $22, Keeps Neutral Rating	23-08-18	MT
Travere Therapeutics' Shares Rise After JPMorgan Initiates Coverage	23-07-21	MT
JPMorgan Initiates Travere Therapeutics With Overweight Rating, $26 Price Target	23-07-21	MT
Canaccord Genuity Adjusts Price Target on Travere Therapeutics to $35 From $37, Maintains Buy Rating	23-07-18	MT
Piper Sandler Assumes Travere Therapeutics at Neutral With $22 Price Target	23-06-07	MT
HC Wainwright Adjusts Price Target on Travere Therapeutics to $35 From $22, Reiterates Buy Rating	23-06-01	MT
TD Cowen Starts Travere Therapeutics at Outperform With $30 Price Target	23-05-22	MT
Wedbush Lowers Travere Therapeutics' Price Target to $23 From $27, Keeps Outperform Rating	23-05-05	MT
HC Wainwright Adjusts Price Target on Travere Therapeutics to $22 From $40, Maintains Buy Rating	23-05-02	MT
BofA Securities Adjusts Price Target on Travere Therapeutics to $39 From $52, Maintains Buy Rating	23-05-02	MT
Evercore ISI Adjusts Price Target on Travere Therapeutics to $26 From $36, Maintains Outperform Rating	23-05-02	MT
Guggenheim Adjusts Price Target on Travere Therapeutics to $23 From $40, Maintains Buy Rating	23-05-02	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.85 USD

Average target price

14.64 USD

Spread / Average Target

+150.31%

High Price Target

21 USD

Spread / Highest target

+258.97%

Low Price Target

9 USD

Spread / Lowest Target

+53.85%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Travere Therapeutics, Inc.

Wedbush
Stifel Nicolaus
Citigroup
JPMorgan Chase
Canaccord Genuity
Guggenheim
Evercore ISI
HC Wainwright
Wells Fargo Securities
William Blair & Co.
Piper Sandler
TD Cowen
BofA Securities
Barclays
SVB Securities LLC
SVB Leerink
BMO Capital

Ratings for Travere Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar